Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial

Obesity

Volumn 19, Issue 1, 2011, Pages 110-120

  Wadden, Thomas A ^a   Foreyt, John P ^b   Foster, Gary D ^c   Hill, James O ^d   Klein, Samuel ^e   O'Neil, Patrick M ^f   Perri, Michael G ^g   Pi Sunyer, F Xavier ^h   Rock, Cheryl L ⁱ   Erickson, Janelle S ^j   Maier, Holly N ^k   Kim, Dennis D ^k   Dunayevich, Eduardo ^k  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SYNEOS HEALTH   (United States)

^k Orexigen Therapeutics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; ANTIDEPRESSANT AGENT; NALTREXONE; NARCOTIC ANTAGONIST; PLACEBO;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISORIENTATION; DISSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METHODOLOGY; MIDDLE AGED; MOOD DISORDER; MORNING DOSAGE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NERVOUSNESS; OBESITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEEP DISORDER; STRESS; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TENSION; TINNITUS; TREATMENT OUTCOME; TREMOR; URTICARIA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; BEHAVIOR THERAPY; BUPROPION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; PLACEBOS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 77956904326     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.147     Document Type: Article

References (32)

1. Naltrexone hydrochloride (naltrexone hydrochloride) [package insert]. Barr Laboratories: Pomona, N Y 2003.
2. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996;15:274-282.
3. Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 16:CD006140.
4. Wellbutrin SR (bupropion hydrochloride) [package insert]. GlaxoSmithKline: Research Triangle Park, NC, 2009.
5. Dhillon S, Yang L P, Curran M P. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008;68:653-689. (Pubitemid 351484811)
6. Stahl SM, Pradko JF, Haight BR et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166.
7. Zyban (bupropion hydrochloride) [package insert]. GlaxoSmithKline: Research Triangle Park, NC 2009.
8. Tong EK, Carmody TP, Simon JA. Bupropion for smoking cessation: a review. Compr Ther 2006;32:26-33.
9. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-39.
10. Greenway FL, Dunayevich E, Tollefson G et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009;94:4898-4906.
11. Cone RD, Cowley MA, Butler AA et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25 (Suppl 5):S63-S67.
12. Cowley MA, Smart JL, Rubinstein M et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411:480-484.
13. Saper CB, Chou TC, Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron 2002;36:199-211.
14. Jain AK, Kaplan RA, Gadde KM et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10: 1049-1056.
15. National Institutes of Health/National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the Evidence Report. Obes Res 1998; 6 (Suppl 2):51S-209S.
16. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-2120.
17. Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med 2009;150:255-262.
18. Brownell KD. The LEARN Program for Weight Control, 7th edn. American Health Publishing: Dallas, 1998.
19. Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
20. National Heart, Lung, and Blood Institute & North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health: Bethesda, MD, 2000.
21. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102-111.
22. White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res 2002;10:107-114.
23. Wilcox CS, Oskooilar N, Erickson JS et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010;35:229-234.
24. Rush AJ, Carmody T, Reimitz, PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:45-59.
25. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002;10:633-641.
26. Vivtrol (naltrexone) [package insert]. Alkermes: Cambridge, MA 2009.
27. Weinsier RL, Ullmann DO. Gallstone formation and weight loss. Obes Res 1993;1:51-56.
28. Kolotkin RL, Norquist JM, Crosby RD et al. One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures. Health Qual Life Outcomes 2009;7:53.
29. Foster GD, Makris A P, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005;82:230S-235S.
30. Hollon SD, DeRubeis RJ. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981;90:467-477.
31. Fabricatore AN, Wadden TA, Moore RH et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333-341.
32. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218-227.